![Proffered paper 2_ELCC 2023](/var/esmo/storage/images/media/esmo-daily-reporter/images/elcc-2023/proffered-paper-2_elcc-20232/17560148-1-eng-GB/proffered-paper-2_elcc-2023_i770.jpg)
Second-line atezolizumab plus cabozantinib fails to improve overall survival in metastatic NSCLC
Final OS analysis of the phase III CONTACT-01 trial reports negative results for immunotherapy versus docetaxel in patients progressing on checkpoint inhibitors plus chemotherapy